Interferon-mediated fatigue

Ummekalsoom R. Malik, Della F. Makower, Scott Wadler

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Fatigue is a common side effect of interferon (IFN) therapy, reported in 70-100% of patients treated with IFN. The etiology of IFN-mediated fatigue (IMF) is multifactorial, with endocrine failure, neuropsychiatric disturbance, autoimmunity, and cytokine dysregulation potentially being contributors. Thyroid dysfunction, associated with the development of autoantibodies, is seen in 8-20% of patients receiving IFN-α. IFN-α also suppresses the hypothalamic-pituitary-adrenal axis. In addition, IFN-α therapy leads to depression and cognitive slowing, and depressed patients are predisposed to develop fatigue. Clinical management of IMF is challenging because the syndrome is variable in onset and severity and the pathophysiology is poorly understood. Current management typically centers on dose reduction, but ancillary nonpharmacologic measures may help improve symptoms. Other strategies include antidepressant or anxiolytic therapy and treatment of coexisting hypothyroidism. Future studies utilizing IFN should include quantitative guidelines for grading and managing IMF.

Original languageEnglish (US)
Pages (from-to)1664-1668
Number of pages5
JournalCancer
Volume92
Issue number6 SUPPL.
StatePublished - Sep 15 2001

Fingerprint

Interferons
Fatigue
Anti-Anxiety Agents
Therapeutics
Hypothyroidism
Autoimmunity
Autoantibodies
Antidepressive Agents
Thyroid Gland
Guidelines
Cytokines

Keywords

  • Autoimmunity
  • Cytokines
  • Fatigue
  • Interferon
  • Nueropsychiatry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Malik, U. R., Makower, D. F., & Wadler, S. (2001). Interferon-mediated fatigue. Cancer, 92(6 SUPPL.), 1664-1668.

Interferon-mediated fatigue. / Malik, Ummekalsoom R.; Makower, Della F.; Wadler, Scott.

In: Cancer, Vol. 92, No. 6 SUPPL., 15.09.2001, p. 1664-1668.

Research output: Contribution to journalArticle

Malik, UR, Makower, DF & Wadler, S 2001, 'Interferon-mediated fatigue', Cancer, vol. 92, no. 6 SUPPL., pp. 1664-1668.
Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001 Sep 15;92(6 SUPPL.):1664-1668.
Malik, Ummekalsoom R. ; Makower, Della F. ; Wadler, Scott. / Interferon-mediated fatigue. In: Cancer. 2001 ; Vol. 92, No. 6 SUPPL. pp. 1664-1668.
@article{3e684b78ec0242788f88b08891e5143e,
title = "Interferon-mediated fatigue",
abstract = "Fatigue is a common side effect of interferon (IFN) therapy, reported in 70-100{\%} of patients treated with IFN. The etiology of IFN-mediated fatigue (IMF) is multifactorial, with endocrine failure, neuropsychiatric disturbance, autoimmunity, and cytokine dysregulation potentially being contributors. Thyroid dysfunction, associated with the development of autoantibodies, is seen in 8-20{\%} of patients receiving IFN-α. IFN-α also suppresses the hypothalamic-pituitary-adrenal axis. In addition, IFN-α therapy leads to depression and cognitive slowing, and depressed patients are predisposed to develop fatigue. Clinical management of IMF is challenging because the syndrome is variable in onset and severity and the pathophysiology is poorly understood. Current management typically centers on dose reduction, but ancillary nonpharmacologic measures may help improve symptoms. Other strategies include antidepressant or anxiolytic therapy and treatment of coexisting hypothyroidism. Future studies utilizing IFN should include quantitative guidelines for grading and managing IMF.",
keywords = "Autoimmunity, Cytokines, Fatigue, Interferon, Nueropsychiatry",
author = "Malik, {Ummekalsoom R.} and Makower, {Della F.} and Scott Wadler",
year = "2001",
month = "9",
day = "15",
language = "English (US)",
volume = "92",
pages = "1664--1668",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Interferon-mediated fatigue

AU - Malik, Ummekalsoom R.

AU - Makower, Della F.

AU - Wadler, Scott

PY - 2001/9/15

Y1 - 2001/9/15

N2 - Fatigue is a common side effect of interferon (IFN) therapy, reported in 70-100% of patients treated with IFN. The etiology of IFN-mediated fatigue (IMF) is multifactorial, with endocrine failure, neuropsychiatric disturbance, autoimmunity, and cytokine dysregulation potentially being contributors. Thyroid dysfunction, associated with the development of autoantibodies, is seen in 8-20% of patients receiving IFN-α. IFN-α also suppresses the hypothalamic-pituitary-adrenal axis. In addition, IFN-α therapy leads to depression and cognitive slowing, and depressed patients are predisposed to develop fatigue. Clinical management of IMF is challenging because the syndrome is variable in onset and severity and the pathophysiology is poorly understood. Current management typically centers on dose reduction, but ancillary nonpharmacologic measures may help improve symptoms. Other strategies include antidepressant or anxiolytic therapy and treatment of coexisting hypothyroidism. Future studies utilizing IFN should include quantitative guidelines for grading and managing IMF.

AB - Fatigue is a common side effect of interferon (IFN) therapy, reported in 70-100% of patients treated with IFN. The etiology of IFN-mediated fatigue (IMF) is multifactorial, with endocrine failure, neuropsychiatric disturbance, autoimmunity, and cytokine dysregulation potentially being contributors. Thyroid dysfunction, associated with the development of autoantibodies, is seen in 8-20% of patients receiving IFN-α. IFN-α also suppresses the hypothalamic-pituitary-adrenal axis. In addition, IFN-α therapy leads to depression and cognitive slowing, and depressed patients are predisposed to develop fatigue. Clinical management of IMF is challenging because the syndrome is variable in onset and severity and the pathophysiology is poorly understood. Current management typically centers on dose reduction, but ancillary nonpharmacologic measures may help improve symptoms. Other strategies include antidepressant or anxiolytic therapy and treatment of coexisting hypothyroidism. Future studies utilizing IFN should include quantitative guidelines for grading and managing IMF.

KW - Autoimmunity

KW - Cytokines

KW - Fatigue

KW - Interferon

KW - Nueropsychiatry

UR - http://www.scopus.com/inward/record.url?scp=0035883485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035883485&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 1664

EP - 1668

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6 SUPPL.

ER -